|
Contingencies (Details Narrative 3) (USD $)
|
3 Months Ended |
|---|---|
|
Sep. 30, 2013
|
|
|
Litigation filed by Daniel Fisher
|
|
| Loss Contingencies [Line Items] | |
| Name of Plaintiff | Daniel Fisher |
| Name of Defendant | BiZone Pharmaceuticals, Inc., Elliot Maza, Brauser Honig Frost Group, Michael Brauser, Barry Honig, and The Frost Group LLC |
| Domicile of Litigation | United States District Court, Northern District of California |
| Case Number | No. 12-03716 |
| Lawsuit Filing Date | 16-Jul-12 |
| Allegations |
Fisher asserts claims for breach of contract, conversion, wrongful termination, and unjust enrichment, and violation of the federal whistleblower statute arising from his former role as an officer and director of the Company and certain contractual agreements that he entered into with the Company. |
| Damages Sought, Value | $ 23,000,000 |
| Actions Taken by Defendant |
This suit was settled on September 10, 2013, see below. |
|
Litigation filed by BioZone Pharmaceuticals, Inc
|
|
| Loss Contingencies [Line Items] | |
| Name of Plaintiff | BioZone Pharmaceuticals, Inc |
| Name of Defendant | Daniel Fisher and 580 Garcia Properties, LLC |
| Domicile of Litigation | Supreme Court of the State of New York, County of New York |
| Case Number | No. 652489/2012 |
| Lawsuit Filing Date | 18-Jul-12 |
| Actions Taken by Defendant |
On September 10, 2013, the Company settled the Fisher litigation by entering into a Settlement Agreement and Mutual Release (the “Settlement Agreement”) among Fisher, the Company, BZL, The Frost Group LLC, BrauserHonig Frost Group, Phillip Frost, Michael Brauser, Barry Honig, Elliot Maza, Brian Keller and Roberto Prego-Novo (collectively, the “Parties” and, individually, as a “Party”) dated as of September 5, 2013. Pursuant to the Settlement Agreement, Fisher dismissed all of his claims contained in the action entitled, Daniel Fisher v. BioZone Pharmaceuticals, Inc., et al., No. 12-CV-03450 (WHA) (LB) United States District Court, Northern District of California, No. 12-03716, in consideration of the Company’s payment to him of the sum of $1,050,000 and the dismissal of the Company’s claims contained in the action entitled, BioZone Pharmaceuticals, Inc. v. Daniel Fisher and 580 Garcia Properties, LLC, Supreme Court of the State of New York, County of New York, No. 652489/2012. Also, pursuant to the Settlement Agreement, Fisher sold his entire holdings of 6,650,000 shares of the Company’s common stock to various private accredited investors. The purchase of Fisher’s shares, which was a condition to the effectiveness of the Settlement Agreement, was completed on September 10, 2013. The Settlement Agreement provides for complete mutual general releases of all claims between the Parties, including but not limited to, all claims arising out of or related to Fisher’s sale of his interest in BZL and related companies to the Company, compensation purportedly owed to Fisher under his terminated employment agreement with the Company and all amounts purportedly owed by the Company, as of the effective date of the Settlement Agreement, to Fisher’s wholly-owned limited liability company, 580 Garcia Properties, LLC (“580 Garcia”) for rent and other amounts due under a written lease between the Company and 580 Garcia. In addition, Fisher agreed to seek the dismissal of all administrative claims and investigations he had instituted with state or Federal agencies against the Company and to remain bound by the non-competition terms contained in his former employment agreement with the Company. None of the Parties admitted to any wrong doing and the Parties agreed not to disparage one another. |